BTIG analyst Mark Massaro reiterated a Buy rating on OncoCyte (OCX – Research Report) yesterday and set a price target of $5.00. The company’s shares closed last Wednesday at $1.66, close to its 52-week low of $1.65.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 11.2% and a 51.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Lucid Diagnostics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 90.1% upside from current levels. In a report issued on January 5, Piper Sandler also initiated coverage with a Buy rating on the stock with a $3.10 price target.
See today’s best-performing stocks on TipRanks >>
OncoCyte’s market cap is currently $153.1M and has a P/E ratio of -4.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
Read More on OCX:
